Drugs

NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Xpovio (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment
0 Comments
Does COVID-19 cause Guillain-Barre Syndrome? A recent study published in Brain describes the findings of a group of researchers who investigated the relationship between the two. Since late 2019, COVID-19 infections have been associated with a wide range of symptoms and illnesses. COVID-19 related neurological conditions have been a cause for concern, specifically Guillain-Barré syndrome
0 Comments
Bacterial infections are experienced by individuals globally. In developing countries, infections are considered one of the largest contributors of death. Antibiotics have been around for over a century, aimed at treating bacterial infections. Due to the prevalence of bacterial infections worldwide, antibiotics are commonly used in healthcare settings for therapeutic treatment. Antibiotics can be used
0 Comments
FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection December 21, 2020 — The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children. Ebanga blocks binding of the virus to the cell receptor, preventing its entry into the
0 Comments
Researchers studied the differences in blood pressure measurements taken from both arms. High blood pressure is one of the leading indicators of cardiovascular disease, which is the number one cause of death in the world. About 1.13 billion people suffer from high blood pressure, although risk factors such as unhealthy diet, sedentary lifestyle, smoking, and
0 Comments
21 December 2020 — AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an
0 Comments
Healthy fats are an important part of a healthy, balanced diet. Fats are often considered to be dangerous due to its association with obesity, heart disease, high cholesterol, and diabetes. However, healthy fats are an essential part of the diet and play a crucial role in maintaining a healthy life. All fats are high in
0 Comments
Sharing a simple meal each day might boost children’s self-esteem according to a new study. Children’s mental health is an important aspect of overall health, and increasing research in this field has shone a light on significant factors that can impact on children’s mental health and self-esteem. However, something as seemingly small as family mealtime
0 Comments
FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix)
0 Comments
infigratinib Treatment for Cholangiocarcinoma of biliary tract BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma PALO ALTO, CA – December 1, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with
0 Comments
The relationship between the gut microbiome and mental health, including how gut bacteria can regulate mood, is explored in a new study by researchers in France. Depression is one of the leading mental health disorders affecting millions of people all over the world. One of the challenges with developing effective treatments for depression is understanding
0 Comments
A recent study reported in Cell demonstrates a new fast and easy point-of-care device for SARS-CoV-2 testing. Decreasing SARS-Cov-2 transmission has proven difficult due to the inability to identify pre-symptomatic, symptomatic, and asymptomatic individuals. Medical communities around the world have spearheaded efforts to develop effective treatments, but proper testing is needed to curb the spread.
0 Comments
ublituximab Treatment for Chronic Lymphocytic Leukemia TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the Company has initiated a rolling submission
0 Comments
FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved Margenza, in
0 Comments
amivantamab Treatment for Non-Small Cell Lung Cancer Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License
0 Comments
South San Francisco, CA — December 14, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Ocrevus® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have
0 Comments
The worldwide impact of influenza on mortality remains one of the most adverse of any infectious disease. In the United States alone, the Centers for Disease Control and Prevention estimate that flu has resulted in between 9 million – 45 million illnesses, between 140,000 – 810,000 hospitalizations, and between 12,000 – 61,000 deaths annually since
0 Comments
Drug used for type 2 diabetes – metformin – may improve COVID-19 outcomes. The SARS-CoV-2 pandemic has spread across the globe with unprecedented speed, affecting every corner of the planet. One of the few positives to emerge from this is the opportunities it has provided for analysing real-world evidence. The pandemic has generated mountains of
0 Comments
Treatment for Eosinophilic Esophagitis U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis Osaka, JAPAN, December 15, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted
0 Comments
FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food
0 Comments
A recent study investigated the mental and physical health of recently divorced men and women. Research on the effects of divorce, in the past few decades, has been consistently showing the negative effects divorce has on both the couple and their children. While such studies have been repeatedly demonstrated in the literature, several limitations have
0 Comments
brincidofovir Treatment for Smallpox Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the
0 Comments
ibrexafungerp Treatment for Vaginal Candidiasis Scynexis Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections JERSEY CITY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) – SCYNEXIS, Inc.,  (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the
0 Comments
Treatment for Congestive Heart Failure scPharmaceuticals Inc. Receives Complete Response Letter from FDA for Furoscix BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today
0 Comments
Treatment for Acne Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo for the Treatment of Acne Vulgaris NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) – Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced
0 Comments
WASHINGTON, Dec. 1, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Hetlioz (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS). SMS is a rare neurodevelopmental disorder, a defining
0 Comments